Drug Discovery and Early Clinical Research
Building bridges between basic research and clinical science.
Drug Discovery and Early Clinical Research
Building bridges between basic research and clinical science.
FUBIS
FUBIS
- FUBIS is a novel drug for targeted treatment of bone metastases and has shown promising results in pre-clinical settings
- FUBIS offers an improved side effect profile allowing for longer and safer treatment, a significant efficacy against osteoclasts and bone metastases in animal models. We expect that FUBIS will level-up specificity and safety for the treatment of bone metastases in clinical trials
- PEKKIP Oncology Alliance has led the development of FUBIS, in a close partnership with the University of Heidelberg and with the National Center for Tumor Diseases (NCT).
- Further development of FUBIS is on the way, aiming to market this novel drug rapidly so that millions of patients may hopefully benefit from it soon
- FUBIS is a novel drug for targeted treatment of bone metastases and has shown promising results in pre-clinical settings
- FUBIS offers an improved side effect profile allowing for longer and safer treatment, a significant efficacy against osteoclasts and bone metastases in animal models. We expect that FUBIS will level-up specificity and safety for the treatment of bone metastases in clinical trials
- PEKKIP Oncology Alliance has led the development of FUBIS, in a close partnership with the University of Heidelberg and with the National Center for Tumor Diseases (NCT).
- Further development of FUBIS is on the way, aiming to market this novel drug rapidly so that millions of patients may hopefully benefit from it soon
